文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

胰腺结石蛋白作为艰难梭菌感染早期预后生物标志物

Pancreatic Stone Protein as an Early Prognostic Biomarker of Outcome in Clostridioides Difficile Infection.
PubMed 文献 · Shock · 2025-11-18
一句话结论前瞻性多中心研究显示,艰难梭菌感染患者起病24小时内胰腺结石蛋白≥300 ng/mL与不良结局独立相关,联合CRP≥90 mg/L预后价值更强。

该前瞻性多中心研究纳入希腊13个中心的147例成人艰难梭菌感染患者,在起病24小时内检测胰腺结石蛋白(PSP)。主要终点为不良结局(器官衰竭、重症进展、复发或死亡至少一项),52例发生不良结局。PSP预测不良结局的曲线下面积为0.648(95%CI 0.550-0.746,P=0.003),最佳截断值300 ng/mL(OR 3.73,95%CI 1.822-7.638,P<0.001)。CRP曲线下面积0.619(95%CI 0.512-0.726,P=0.03),最佳截断值≥90 mg/L。PSP与CRP联合升高预后价值更强(OR 7.04,95%CI 2.78-17.85,P<0.001)。多因素分析中PSP≥300 ng/mL(P=0.006)和CRP≥90 mg/L(P=0.04)均与不良结局独立相关。作者认为PSP尤其联合CRP可能作为早期风险分层的补充生物标志物。

要点

  • 147例成人艰难梭菌感染患者中52例发生不良结局,PSP在起病24小时内检测。
  • PSP预测不良结局的AUC为0.648(95%CI 0.550-0.746,P=0.003),最佳截断值300 ng/mL。
  • PSP≥300 ng/mL与不良结局风险升高相关(OR 3.73,95%CI 1.822-7.638,P<0.001)。
  • PSP与CRP联合升高预后价值更强(OR 7.04,95%CI 2.78-17.85,P<0.001)。
  • 多因素分析中PSP≥300 ng/mL(P=0.006)和CRP≥90 mg/L(P=0.04)均独立相关。

适用人群与场景

  • 希腊13个研究中心的成人艰难梭菌感染患者。

诊断标准与关键阈值

  • 不良结局定义为器官衰竭、重症疾病进展、复发或死亡中至少一项。
  • PSP预测不良结局最佳截断值300 ng/mL。
  • CRP预测不良结局最佳截断值≥90 mg/L。

研究设计与关键结果

  • 前瞻性多中心研究纳入147例成人艰难梭菌感染患者,52例发生不良结局。
  • 不良结局患者PSP水平显著更高。
  • PSP预测不良结局AUC 0.648(95%CI 0.550-0.746,P=0.003),最佳截断值300 ng/mL,OR 3.73(95%CI 1.822-7.638,P<0.001)。
  • CRP预测不良结局AUC 0.619(95%CI 0.512-0.726,P=0.03),最佳截断值≥90 mg/L。
  • PSP与CRP联合升高OR 7.04(95%CI 2.78-17.85,P<0.001)。
  • 多因素分析中PSP≥300 ng/mL(P=0.006)和CRP≥90 mg/L(P=0.04)仍与不良结局独立相关。

证据类型、等级与局限

  • 证据类型:前瞻性多中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于成人艰难梭菌感染患者,起病24小时内检测PSP可能有助于早期风险分层(作者认为)。
  • PSP联合CRP可能作为补充生物标志物用于识别不良结局高风险患者(作者认为)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Clostridioides difficile infection (CDI) remains a major healthcare-associated infection, leading to severe complications. Early identification of patients at high risk for unfavorable outcomes remains challenging. Pancreatic stone protein (PSP) has emerged as a promising biomarker in sepsis; however, its role in CDI has not been investigated.

MATERIALS AND METHODS: We conducted a prospective multicenter study of adult patients with CDI from 13 study sites in Greece. PSP was measured within 24 hours of CDI onset. The primary outcome was the association between PSP and unfavorable outcome, defined as at least one of the following: organ failure, severe disease progression, relapse, or death. Receiver operating characteristic curve was performed to assess diagnostic performance, and multivariate logistic regression to evaluate independent predictors of adverse outcome.

RESULTS: One hundred forty-seven patients were enrolled, and unfavorable outcomes occurred in 52. PSP levels were significantly higher in these patients. PSP showed an area under the curve of 0.648 [95% confidence interval (CI) 0.550-0.746, P = 0.003] for predicting adverse outcome and an optimal cutoff of 300 ng/mL, which increased the risk significantly (odds ratio 3.73, 95% CI 1.822-7.638, P < 0.001). C-reactive protein (CRP) was also associated with adverse outcome (area under the curve 0.619, 95% CI 0.512-0.726, P : 0.03), with an optimal cutoff ≥90 mg/L. Combined elevation of PSP and CRP conferred stronger prognostic value (odds ratio 7.04, 95% CI 2.78-17.85, P < 0.001). In multivariate analysis, PSP ≥300 ng/mL ( P : 0.006) and CRP ≥90 mg/L ( P : 0.04) remained independently associated with unfavorable outcome.

CONCLUSIONS: This is the first study evaluating PSP in CDI. PSP, especially combined with CRP, may serve as complementary biomarkers for early risk stratification.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Tziolos RN, Psarrakis C, Koufargyris P, et al. Pancreatic Stone Protein as an Early Prognostic Biomarker of Outcome in Clostridioides Difficile Infection. Shock. 2025. PMID: 41427863. doi:10.1097/SHK.0000000000002759

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。